354 related articles for article (PubMed ID: 21486728)
21. Rare form of semi-invasive aspergillosis in immunocompetent patient: case report.
Croitoru A; Melloni B; Dupuy-Grasset M; Darde ML; Delage M; Bonnaud F
Pneumologia; 2011; 60(4):222-4. PubMed ID: 22420173
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of concomitant pulmonary zygomycosis and aspergillosis with a combination of amphotericin B lipid complex, caspofungin, and voriconazole in a patient on immunosuppression for chronic graft-versus-host disease.
Verma A; Williams S; Trifilio S; Zembower T; Mehta J
Bone Marrow Transplant; 2004 May; 33(10):1065-6. PubMed ID: 15048146
[No Abstract] [Full Text] [Related]
23. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study.
Tan BH; Low JG; Chlebicka NL; Kurup A; Cheah FK; Lin RT; Goh YT; Wong GC
Int J Infect Dis; 2011 May; 15(5):e350-6. PubMed ID: 21397541
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
Hiemenz JW; Raad II; Maertens JA; Hachem RY; Saah AJ; Sable CA; Chodakewitz JA; Severino ME; Saddier P; Berman RS; Ryan DM; Dinubile MJ; Patterson TF; Denning DW; Walsh TJ
Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1387-94. PubMed ID: 20703506
[TBL] [Abstract][Full Text] [Related]
25. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.
Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C
Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414
[TBL] [Abstract][Full Text] [Related]
26. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
Almyroudis NG; Sutton DA; Fothergill AW; Rinaldi MG; Kusne S
Antimicrob Agents Chemother; 2007 Jul; 51(7):2587-90. PubMed ID: 17452481
[TBL] [Abstract][Full Text] [Related]
27. A case of Aspergillus mediastinitis after heart transplantation successfully treated with liposomal amphotericin B, caspofungin and voriconazole.
Forestier E; Remy V; Lesens O; Martinot M; Hansman Y; Eisenmann B; Christmann D
Eur J Clin Microbiol Infect Dis; 2005 May; 24(5):347-9. PubMed ID: 15889298
[TBL] [Abstract][Full Text] [Related]
28. Invasive Aspergillus fumigatus infection after Plasmodium falciparum malaria in an immuno-competent host: case report and review of literature.
Eckerle I; Ebinger D; Gotthardt D; Eberhardt R; Schnabel PA; Stremmel W; Junghanss T; Eisenbach C
Malar J; 2009 Jul; 8():167. PubMed ID: 19619319
[TBL] [Abstract][Full Text] [Related]
29. [Addressing the "Hot Spots" in the management of invasive aspergillosis].
Kontoyiannis D
Med Mal Infect; 2007; 37 Suppl 2():9-11. PubMed ID: 17933659
[TBL] [Abstract][Full Text] [Related]
30. An update on the use of antifungal agents.
Martinez R
J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
[TBL] [Abstract][Full Text] [Related]
31. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.
Madureira A; Bergeron A; Lacroix C; Robin M; Rocha V; de Latour RP; Ferry C; Devergie A; Lapalu J; Gluckmana E; Socié G; Ghannoum M; Ribaud P
Int J Antimicrob Agents; 2007 Dec; 30(6):551-4. PubMed ID: 18029149
[TBL] [Abstract][Full Text] [Related]
32. Use of newer antifungal therapies in clinical practice: what do the data tell us?
Perfect JR
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):15-23. PubMed ID: 15651178
[TBL] [Abstract][Full Text] [Related]
33. The effects of caspofungin and voriconazole in an experimental fungal infection of the ear due to Aspergillus.
Ayçiçek A; Cetinkaya Z; Kiyici H; Kenar F; Aşik G; Kiraz N
Eur Arch Otorhinolaryngol; 2009 Nov; 266(11):1703-9. PubMed ID: 19340446
[TBL] [Abstract][Full Text] [Related]
34. New antifungal agents.
Gupta AK; Tomas E
Dermatol Clin; 2003 Jul; 21(3):565-76. PubMed ID: 12956208
[TBL] [Abstract][Full Text] [Related]
35. [Ambulatory therapy of aspergillosis in hematological and oncological patients].
Egerer G
Mycoses; 2012 Jul; 55 Suppl 2():30-4. PubMed ID: 22519630
[No Abstract] [Full Text] [Related]
36. Combination antifungal therapy for invasive aspergillosis.
Cesaro S; Visintin G
Clin Infect Dis; 2005 Apr; 40(7):1073-5; author reply 1075-6. PubMed ID: 15825015
[No Abstract] [Full Text] [Related]
37. Combination antifungal therapy for invasive pulmonary aspergillosis.
Abdulaziz S; Al Jahdali H; Baharoon S
BMJ Case Rep; 2012 Dec; 2012():. PubMed ID: 23242100
[No Abstract] [Full Text] [Related]
38. Invasive pulmonary infection due to Trichoderma longibrachiatum mimicking invasive Aspergillosis in a neutropenic patient successfully treated with voriconazole combined with caspofungin.
Alanio A; Brethon B; Feuilhade de Chauvin M; de Kerviler E; Leblanc T; Lacroix C; Baruchel A; Menotti J
Clin Infect Dis; 2008 May; 46(10):e116-8. PubMed ID: 18419477
[TBL] [Abstract][Full Text] [Related]
39. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.
Singh N; Limaye AP; Forrest G; Safdar N; Muñoz P; Pursell K; Houston S; Rosso F; Montoya JG; Patton P; Del Busto R; Aguado JM; Fisher RA; Klintmalm GB; Miller R; Wagener MM; Lewis RE; Kontoyiannis DP; Husain S
Transplantation; 2006 Feb; 81(3):320-6. PubMed ID: 16477215
[TBL] [Abstract][Full Text] [Related]
40. [New antifungal agents: voriconazole and caspofungin].
Dupont B
Arch Pediatr; 2003 Dec; 10 Suppl 5():592s-598s. PubMed ID: 15022787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
